

PRESS RELEASE

Number 10

WACKER BIOSOLUTIONS Under New Leadership

Munich, March 30, 2020 – Dr. Susanne Leonhartsberger (48) takes over as president of WACKER BIOSOLUTIONS on April 1, 2020. She succeeds Dr. Gerhard Schmid (65), who retires on March 31, 2020. Dr. Leonhartsberger's last position was managing director of Wacker Biotech GmbH and, as head of WACKER's biopharma business line, she was responsible for biologics business.

Dr. Susanne Leonhartsberger studied biology at Ludwig-Maximilians University in Munich, where she wrote her doctorate on the gene regulation activities and biochemistry of bacteria. She first joined Roche Diagnostics, where she worked in protein production. In 2001, she moved to WACKER's Corporate R&D department. After various positions at Wacker Biotech's site in Jena and at the Corporate Development department in Munich, she moved to Adrian (USA) in 2014. There, she headed WACKER BIOSOLUTIONS' North and Central America business until 2017. On her return to Germany, she became managing director of Wacker Biotech GmbH and, as head of the biopharma business line, was responsible for biologics contract-manufacturing at WACKER.

As of April 1, Dr. Guido Seidel, currently second managing director of Wacker Biotech GmbH, will succeed Dr. Leonhartsberger as head of

the biopharma line and first managing director of Wacker Biotech GmbH. Effective the same date, Melanie Käsmarker becomes second managing director of Wacker Biotech GmbH. Currently, Melanie Käsmarker heads the Global Finance & Administration unit for the biopharma business line and, at the same time, is site manager at Wacker Biotech's site in Halle. Wacker Biotech is a wholly-owned WACKER subsidiary.

About WACKER BIOSOLUTIONS

Using advanced biotech processes, WACKER BIOSOLUTIONS provides tailored, innovative solutions and products to the life-science sector – including pharmaceutical proteins, cyclodextrins and fermentation-generated cysteine. Its portfolio is complemented by catalog chemicals, such as acetylacetone and high-quality polyvinyl acetate solid resins. The division focuses on producing customized solutions for growth areas, such as food ingredients, pharmaceutical actives and agrochemicals.



Dr. Susanne Leonhartsberger (48) will head Wacker Chemie AG's WACKER BIOSOLUTIONS division as of April 1, 2020. (Photo: Wacker Chemie AG)

Note:

You can download this photo at:

<http://www.wacker.com/pressreleases>

For further information, please contact:

Wacker Chemie AG
Media Relations & Information
Manuela Dollinger
Tel. +49 89 6279-1629
manuela.dollinger@wacker.com
www.wacker.com
follow us on:   

The company in brief:

WACKER is a globally-active chemical company with some 14,700 employees and annual sales of around € 4.93 billion (2019). WACKER has a global network of 24 production sites, 23 technical competence centers and 51 sales offices.

WACKER SILICONES

Silicone fluids, emulsions, rubber grades and resins; silanes; pyrogenic silicas; thermoplastic silicone elastomers

WACKER POLYMERS

Polyvinyl acetates and vinyl acetate copolymers and terpolymers in the form of dispersible polymer powders, dispersions, solid resins and solutions

WACKER BIOSOLUTIONS

Biotech products such as cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins

WACKER POLYSILICON

Polysilicon for the semiconductor and photovoltaic industries